Sage Therapeutics has scored a big win with postpartum depression (PPD) drug SAGE-217, after rolling the dice on an upgraded clinical trial last summer.
Sage’s Zulresso (brexanolone) is on course for approval for postnatal depression in the US after a positive vote from an FDA advisory committee at its meeting last week, but the same panel had bad